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According to the concept of apolipoprotein (apo)-defined
lipoproteins, apoA-I-containing lipoproteins consist of two
subclasses referred to as lipoprotein A-I (LpA-I) and
lipoprotein A-I:A-II (LpA-I:A-II), and apoB-containing
lipoproteins of five subclasses, namely lipoprotein B (LpB),
lipoprotein B:C (LpB:C), lipoprotein B:E (LpB:E), lipoprotein
B:C:E (LpB:C:E), and lipoprotein A-II:B:C:D:E (LpA-II:B:C:D:E).
The purpose of this study was to determine the levels of
apoA-I- and apoB-containing lipoprotein subclasses before
and after fluvastatin treatment of patients with chronic renal
insufficiency. ApoA-I- and apoB-containing lipoprotein
subclasses were measured in 15 patients with chronic renal
failure and 15 asymptomatic subjects. The effect of
fluvastatin on lipoprotein subclasses was determined in a
randomized, double-blind, placebo-controlled, two-way,
treatment period crossover study. Patients were
administered fluvastatin 40 mg/day or placebo during 8
weeks in a randomized order. Patients were characterized by
significantly higher levels of LpB (Po0.001), LpB:C (Po0.001),
and LpB:E (Po0.05), and slightly higher levels of LpB:C:E and
LpA-II:B:C:D:E than controls. The levels of LpA-I:A-II were
significantly lower (Po0.01) in patients than controls.
Fluvastatin treatment reduced all apoB-containing
subclasses, but only the reduced level of LpB subclass was
statistically significant (Po0.02). The levels of LpA-I and
LpA-I:A-II were not affected. Fluvastatin treatment reduced
and normalized LpB and LpB:E subclasses. Although slightly
reduced, the levels of markedly atherogenic LpB:C subclass
were not normalized. The potential role of LpB:C on the
progression of coronary artery disease in chronic renal
insufficiency remains to be determined in future studies.
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Traditionally, the lipoprotein abnormalities of chronic renal
insufficiency have been characterized in terms of concentra-
tion changes in major lipoprotein density classes. Accord-
ingly, renal dyslipoproteinemia has been broadly
characterized by increased levels of very low- (VLDL) and
intermediate-density (IDL) lipoproteins, unchanged or
moderately raised levels of low-density (LDL) lipoproteins,
and decreased levels of high-density lipoproteins (HDL).1
However, studies on the apolipoprotein (apo) composition
and immunochemical and kinetic properties have revealed a
marked chemical and metabolic heterogeneity of major
lipoprotein density classes, which has been accounted for by
the occurrence of discrete lipoprotein subclasses character-
ized by similar density properties but specific qualitative apo
composition.2 These findings led to the introduction of an
alternative classification system of lipoproteins based on apo
composition rather than physical properties as the main
criterion for their identification and differentiation.2 This
classification system recognizes two lipoprotein classes, one
of which is characterized by apoA and the other by apoB as
the major lipoprotein constituents. The former lipoprotein
class consists of two major lipoprotein subclasses named
according to their apo composition, lipoprotein A-I (LpA-I)
and lipoprotein A-I:A-II (LpA-I:A-II), whereas the latter
encompasses five major subclasses called lipoprotein B (LpB),
lipoprotein B:E (LpB:E), lipoprotein B:C (LpB:C), lipopro-
tein B:C:E (LpB:C:E), and lipoprotein A-II:B:C:D:E (LpA-
II:B:C:D:E).2,3 Each of these lipoprotein subclasses is
characterized not only by a unique apo composition but
also by specific metabolic and functional properties.2,3
Furthermore, it appears that apoB-containing lipoprotein
subclasses may differ in their atherogenic capacities3–5
and apoA-containing lipoproteins in their antiatherogenic
potentials.3,6–8
The subfractionation and quantification of individual
apo-defined subclasses required the use of specific immuno-
logic methods such as immunoprecipitation2,9,10 and/or
immunoaffinity chromatography.2,11 A stepwise immunoaf-
finity chromatographic procedure developed for separating
and quantifying five apoB-containing lipoprotein subclasses
has now been applied, for the first time, to the determination
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of apo-defined lipoprotein subclass profiles in patients with
chronic renal insufficiency and subjects with asymptomatic
normolipidemia.
In our recent study on the modulation of renal
dyslipoproteinemia by fluvastatin,12 a synthetic hydroxy-
methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor,
we have shown that this statin was quite effective in reducing
and normalizing lipid and apo constituents of cholesterol-
rich lipoproteins, but less effective in lowering those of
triglyceride (TG)-rich apoB-containing lipoproteins. Thus,
the purpose of this study was to determine by use of a
stepwise immunoaffinity chromatography procedure both
the lipoprotein concentration profile and the effect of
fluvastatin on five apoB-containing lipoprotein subclasses
in patients with moderately advanced renal insufficiency.
RESULTS
ApoB-containing lipoprotein subclasses
As shown in the initial report of the fluvastatin intervention
trial,12 patients with renal insufficiency had significantly
higher concentrations of total cholesterol (TC), TG, VLDL-C,
and LDL-C and lower levels of HDL-C than control subjects.
Similarly, the concentrations of apoB, apoC-III, and apoE
were significantly higher in patients than controls. The
slightly lower levels of apoA-I in patients compared to those
in controls were not statistically significant. In comparison
with controls, patients had significantly higher levels of
apoC-III bound to apoB-containing lipoproteins (apoC-III-
heparin-manganese precipitate), but their slightly higher
levels of apoC-III bound to apoA-containing lipoproteins
(apoC-III-heparin-manganese supernate) did not reach
statistical significance.
The measurement of discrete apoA-containing lipoprotein
subclasses showed that patients with renal insufficiency had
normal levels of putative antiatherogenic LpA-I particles,
but significantly decreased levels of LpA-I:A-II particles
compared to control subjects.12 Thus, the lower levels of
plasma apoA-I in chronic renal insufficiency were owing to a
decrease in the concentration of LpA-I:A-II rather than LpA-I
particles.
By using the newly developed immunoaffinity chromato-
graphic procedure, it was possible to determine for the first
time the concentrations of five discrete apoB-containing
lipoprotein subclasses in renal patients and asymptomatic
controls (Tables 1 and 2). The lipoprotein subclass profile
of fasting normolipidemic subjects was characterized by
cholesterol-enriched LpB and LpB:E particles as the main
lipoprotein species of predominantly low-density properties
accounting for 75% of the total apoB-containing lipopro-
teins. The intact and partially delipidized TG-rich LpB:C,
LpB:C:E, and LpA-II:B:C:D:E particles of mainly very low-
and intermediate-density characteristics accounted for 25%
of the remaining apoB-containing lipoproteins. In patients
with renal insufficiency, the levels of all five apoB-containing
lipoprotein subclasses were found to be elevated in
comparison with those of control subjects. The increased
concentrations of plasma apoB and apoC-III reflected
significantly increased levels of cholesterol-enriched LpB
and TG-rich LpB:C particles rather than slightly, but non-
significantly, elevated levels of LpB:E, LpB:C:E, and LpA-
II:B:C:D:E particles.
Effect of fluvastatin on ApoB-containing lipoprotein
subclasses
Renal patients randomized into placebo and fluvastatin
treatment had comparable values for plasma lipids (Table 3),
apo’s (Table 4), and individual apoA- and apoB-containing
lipoprotein subclasses at the start of each treatment period
(Tables 3–5). TC (18%) and LDL-C (25.5%) were
significantly reduced (P¼ 0.001) by fluvastatin treatment. A
slight reduction in the levels of TG (13%) and VLDL-C
(11%) was not significant, whereas the concentration of
HDL-C remained unchanged (Table 3).
Among plasma apo’s, only the apoB (18%) and apoE
(15%) were significantly reduced by fluvastatin (Table 4).
Although plasma apoC-III levels remained unchanged,
fluvastatin treatment influenced moderately the distribution
of apoC-III between apoA- and apoB-containing lipopro-
teins. There was a slight reduction of apoC-III bound to
apoB-containing lipoproteins (apoC-III-heparin-manganese
precipitate) and a corresponding elevation of apoC-III bound
to apoA-containing lipoproteins (apoC-III-heparin-manga-
nese supernate); the resulting increase in the apoC-III-ratio
(þ 18%) suggested a slightly enhanced catabolism of TG-rich
Table 1 | Patient characteristics at study entry
Characteristics Men Women
Sex (n) 10 5
Age (year) 57.0711.7 57.9712.4
Weight (kg) 80.178.1 73.0712.2
Height (cm) 180.574.8 169.879.0
Body mass index (kg/m2 body surface area) 24.672.9 25.272.8
Duration, chronic renal disease (year) 14.9711.9 17.671.6
GFR (ml/min 1.73 m2 BSA) 33.978.9 20.871.2
BSA, bovine serum albumin; GFR, glomerular filtration rate. Values are expressed as
number of mean7s.d.
Table 2 | ApoB-containing lipoprotein particles in plasma of
patients with chronic renal failure before dialysis and
normolipidemic asymptomatic controls
Lipoprotein
Chronic renal
failure (mg/dl)
Normolipidemic
asymptomatic controls
particles n=15 n=15 P-value*
ApoB 136.6739.5 93.6728.7 o0.001
ApoC-III 19.277.8 10.072.7 o0.001
LpB 82.1729.6 55.9720.8 o0.001
LpB:E 20.277.5 14.575.5 o0.05
LpB:C 20.3710.1 10.473.7 o0.001
LpB:C:E 2.173.6 1.171.4 NS
LpA-II:B:C:D:E 11.975.6 11.274.0 NS
apo, apolipoprotein; Lp, lipoprotein; NS, non-significnt.
*Student’s t-test.
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lipoproteins. Fluvastatin treatment had no effect on apoA-I
levels.
All four major apoB-containing lipoprotein subclasses
were reduced by fluvastatin treatment, with the exception of
low levels of LpB:C:E subclass (Table 5). However, only the
reduced concentration of cholesterol-rich LpB subclass was
statistically significant. A comparison between fluvastatin-
treated patients (Table 5) and normolipidemic controls
(Table 2) showed that fluvastatin not only reduced but
almost normalized the cholesterol-enriched LpB and LpB:E
subclasses and their characteristic constituents, including
plasma TC, LDL-C, apoB, and apoE. In contrast, the levels of
intact or partially delipidized LpB:C subclass and the
corresponding constituents such as plasma TG, VLDL-C,
apoC-III, and apoC-III-heparin-manganese precipitate were
reduced, but not normalized; differences between normal and
treatment values of these variables remained statistically
significant (Po0.01).
Adverse events
Fluvastatin was generally well tolerated. As already presented
for the whole cohort of 48 patients with chronic renal
failure treated with fluvastatin,12 there were 37 non-serious
adverse events in 22 patients during fluvastatin treatment,
and 49 non-serious adverse events in 28 patients during
placebo therapy. The most common reports were gastro-
intestinal symptoms of various types (diarrhea, dyspepsia,
nausea, abdominal pain, and constipation) with no
difference in frequencies between placebo and active
treatments. All 15 patients selected for the measurement
of apoA- and apoB-containing lipoprotein subclasses
completed the study.
Table 3 | Plasma concentrations of lipids before and after treatment with placebo and fluvastatin
(n=15)
Placebo (mg/dl) Fluvastatin
Adjusted treatment
Baseline 8 weeks Baseline 8 weeks effect (%) P-value
TC 248.3754.2 239.6753.3 240.3758.2 190.8742.3 18.0 0.001
VLDL-C 36.8717.2 32.8714.0 35.9713.1 28.170.1 11.0 40.20
LDL-C 167.6748.9 161.6742.0 159.5756.7 113.4734.7 25.5 0.001
HDL-C 39.977.5 38.476.6 42.376.9 41.579.2 1.9 40.20
TG 225.57137.1 209.97136.2 213.87108.6 169.87108.3 13.1 40.20
HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; TC, total cholesterol; TG, triglyceride; VLDL-C, very low-density lipoprotein-cholesterol.
Values are expressed as mean7s.d.
Table 4 | Plasma concentrations of apo’s before and after treatment with placebo and fluvastatin
(n=15)
Placebo (mg/dl) Fluvastatin
Adjusted treatment
Baseline 8 weeks Baseline 8 weeks effect (%) P-value
ApoA-I 128.6718.1 126.3714.7 125.2712.9 131.5715.6 6 0.10
ApoB 141.0737.6 140.0738.6 135.4738.0 109.7732.0 18 0.0001
ApoC-III 20.579.6 19.2710.3 19.377.7 18.278.5 0.2 40.20
ApoE 11.774.7 11.073.8 11.773.8 9.272.4 15 0.01
ApoC-III-HS 7.974.3 7.072.7 6.973.0 7.672.6 1 0.14
ApoC-III-HP 10.576.7 10.878.0 11.476.3 8.976.1 20 0.07
ApoC-III-ratio 1.1671.35 0.8870.53 0.7270.37 1.1470.84 18 0.08
Apo, apolipoprotein; HP, heparin-manganese precipitate; HS, heparin-manganese supernate. Values expressed as mean7s.d.
Table 5 | Plasma concentrations of ApoA-I- and ApoB-containing lipoprotein subclasses before and after treatment with
placebo and fluvastatin
(n=15)
Placebo (mg/dl) Fluvastatin
Adjusted treatment
Baseline 8 weeks Baseline 8 weeks effect (%) P-value
LpA-I 32.975.6 31.674.4 33.674.3 35.176.8 7 0.19
LpA-I:A-II 95.7713.6 94.7710.7 91.679.8 96.4711.1 5 40.20
LpB 85.4725.7 81.7730.6 81.0730.1 64.4725.4 15 0.02
LpB:E 20.277.0 19.876.0 19.877.1 14.176.4 26 0.16
LpB:C 19.3710.1 21.071.01 20.078.3 17.679.3 19 0.12
LpB:C:E 2.273.5 1.672.5 1.473.2 1.973.0 79 40.20
LpA-II:B:C:D:E 13.473.9 13.576.0 15.475.8 11.875.3 22 0.11
Apo, apolipoprotein; Lp, lipoprotein. Values expressed as mean7s.d.
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DISCUSSION
Results of this and previous studies12–15 have shown that in
renal insufficiency the profile of individual apoA-containing
lipoprotein subclasses is characterized by normal levels of
LpA-I and slightly to moderately reduced levels of LpA-I:A-II
subclasses. If one considers that LpA-I subclass represents the
antiatherogenic factor of apoA-containing lipoproteins or
HDL, a moderate decrease in the levels of LpA-I:A-II, but not
LpA-I, might be of little clinical significance.
The measurement of individual apoB-containing lipopro-
tein subclasses in the present study has indicated that
significantly elevated concentrations of cholesterol-rich LpB
and TG-rich LpB:C are the most characteristic abnormalities
of dyslipoproteinemia of chronic renal failure. What might be
a clinically significant aspect of this lipoprotein profile is the
occurrence of relatively high levels of LpB and LpB:C
subclasses considered to be the most atherogenic among
the apoB-containing lipoproteins. As the main subclass of
LDL, the LpB particles have been shown to have a significant
atherogenic potential based indirectly on a number of lipid-
lowering trials16 and by their direct measurement and
association with the progression of atherosclerotic lesions
in the Monitored Atherosclerosis Regression Study.17 Simi-
larly, it was suggested in the Cholesterol Lowering Athero-
sclerotic Study18 as well as in the Monitored Atherosclerosis
Regression Study and Cholesterol and Recurrent Events
ancillary studies19 that intact or partially delipidized apoB-
containing lipoproteins enriched with apoC-III may have
atherogenic potential similar to that of LpB. The concentra-
tions of LpB:C, but not LpB or LpB:C:E, were found to be
significantly higher in predialytic subjects with chronic renal
insufficiency than in corresponding controls.20 In a recently
reported ancillary Cholesterol and Recurrent Events study,5
the measurement of LpB and LpB:C in the intermediate-
density lipoprotein and LDL of subjects with type II diabetes
provided the first opportunity to compare the predictive
power of these two atherogenic subclasses. The results
showed that LpB:C particles were a several-fold greater
predictor of recurrent coronary events than LpB particles and
that the relationship of LpB:C and coronary events was
independent of lipid and apo risk factors. This important
finding, suggesting that the LpB:C subclass may have a
greater atherogenic potential than the LpB subclass, has
provided additional evidence for the concept of the relative
atherogenicity of individual apoB-containing lipoproteins.2
Based on these findings, increased levels of both cholesterol-
rich LpB and intact or partially delipidized TG-rich LpB:C
subclasses ought to be considered as the main target of thera-
peutic intervention in patients with chronic renal failure.
To explore the effect of pharmacologic agents on the levels
of LpB and LpB:C subclasses in patients with chronic renal
failure, we have selected fluvastatin for the initial study,
because this HMG-CoA reductase inhibitor has already been
shown to be an efficient drug for lowering apoB-containing
lipoproteins and plasma apo’s C-III and E,21–27 to have
a good safety record in hyperlipidemic subjects,24,26–32
favorable pharmacokinetic profile in patients with impaired
renal function,12 and an equally angiographic and clinical
benefit, especially in non-renal patients with coronary artery
disease.31–34 As expected of a statin, fluvastatin reduced and,
more importantly, normalized the levels of cholesterol-rich
LpB and LpB:E subclasses, including their characteristic lipid
and apo constituents (TC, LDL-C apoB, and apoE). In
contrast, fluvastatin had very little effect in reducing and
normalizing the concentration of atherogenic, TG-enriched
LpB:C particles, or VLDL-C, TG, and apoC-III. There was
practically no effect on the levels of TG-rich LpB:C:E and
only a slight lowering effect on the levels of LpA-II:B:C:D:E.
These findings confirm the well-established lowering effect of
fluvastatin on cholesterol-rich apoB-containing lipoproteins
in hypercholesterolemia,21,27,30–32,35 combined hyperlipide-
mia,36 type II diabetes,28 and chronic renal failure.12,37 A
small insignificant lowering effect of fluvastatin on plasma
levels of TGs and apoC-III, as reflected in practically
unchanged concentrations of TG-rich apoB-containing sub-
classes presented in this study, is consistent with the results of
a number of studies showing minimal27,29–32,36,38–40 or
moderate24–26,28,34,41 lowering effect of fluvastatin on the
levels of TGs and apoC-III. Although it appears that
treatment with fluvastatin is more effective in reducing
cholesterol-rich than TG-rich apoB-containing lipoprotein
subclasses, it was shown in non-renal patients with mild to
moderate cholesterol elevation31,34 and in patients following
successful percutaneous coronary intervention41 that fluvas-
tatin treatment reduced insignificantly in some cases31 and
significantly in other34,41 the risk of major adverse cardiac
events. While this effect may be attributed to lowering of the
cholesterol-rich LpB and/or LpB:E subclasses, the lack of
fluvastatin capacity to lower or normalize the levels of intact
or partially delipidized TG-rich apoB-containing lipoprotein
subclasses may diminish its overall antiatherosclerotic
potential. The already observed contribution of complex
TG-rich apoB-containing lipoprotein subclasses to the pro-
gression of renal dysfunction42 in concert with the evidence
for a significant role of hypertriglyceridemia in the develop-
ment of endothelial dysfunction43–45 and coronary heart
disease46 suggest strongly that increased levels of some
TG-rich lipoproteins may also be a significant risk factor for
the progression of coronary artery disease in renal insuffi-
ciency. It should be emphasized, however, that the relative
contribution of cholesterol-rich and TG-rich apoB-contain-
ing lipoproteins to the progression of atherosclerosis in renal
insufficiency remains to be determined in a clinical trial
specifically designed to test this still unanswered question
regarding the complex nature of renal dyslipoproteinemia. In
this respect, it has recently been reported47 that, despite a
42% decrease in the levels of LDL-cholesterol, atorvastatin
had no significant effect on the incidence of cardiovascular
and cerebrovascular events in patients with type II diabetes
undergoing hemodialysis; it has not been established, how-
ever, to what extent increased levels of TG-rich lipoproteins
might have contributed to the negative outcome of this trial.
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In conclusion, this is the first study characterizing
dyslipoproteinemia of chronic renal failure based on apo-
defined apoB-containing lipoprotein subclasses. By using a
three-step immunoaffinity chromatography, chronic renal
failure was characterized by significantly increased levels of
cholesterol-rich LpB and LpB:E and TG-rich LpB:C sub-
classes and moderately increased levels of TG-rich LpB:C:E
and LpA-II:B:C:D:E subclasses in comparison with asympto-
matic, normolipidemic controls.
Intervention with fluvastatin resulted in reduction and
normalization of main constituents and number of choles-
terol-rich LpB and LpB:E and TG-rich LpB:C:E and LpA-
II:B:C:D:E; however, the levels of TG-rich LpB:C particles
considered to be of substantial atherogenic capacity were
slightly reduced, but not normalized. The potential role of
LpB:C subclass in the initiation and progression of coronary
atherosclerotic disease in chronic renal failure remains to be
determined in future studies.
MATERIALS AND METHODS
Study group
Fifteen patients (10 men and 5 women) with chronic renal disease
were included in the study and randomized to receive fluvastatin
40 mg once daily or placebo. Only non-nephrotic patients with
primary chronic renal disease and moderate to advanced renal
insufficiency were eligible for the study. Patients with secondary
renal disease (such as diabetes mellitus), ongoing immunosuppres-
sive treatment, ongoing estrogen therapy, and lipid-lowering therapy
were excluded from this study.
All 15 patients completed fluvastatin and placebo treatments.
Patients’ mean age was 57.7711.7 years. The average glomerular
filtration rate was 33.978.9 ml/min/1.75 m2 body surface area for
men and 20.8 for women. The entry characteristics of the patient
study group are presented in Table 1.
Control subjects were recruited among asymptomatic, normo-
lipidemic Swedish subjects, employees of the Department of
Nephrology, University of Go¨teborg, Sweden. The control popula-
tion consisted of 15 subjects (10 men and 5 women) with mean age
4979 years.
Study design
The study was a randomized, double-blind, placebo-controlled, two-
way, treatment period crossover study. The patients received
fluvastatin 40 mg once daily or corresponding placebo in rando-
mized order. Each treatment period was 8 weeks long and divided by
an 8-week-long wash-out period.
Plasma lipids and apo’s
Venous blood samples were drawn into ethylenediamine tetra-
acetate-containing vacutainer tubes after an overnight fast (8 h or
more) with patients and controls in the recumbent position, and
plasma samples were recovered by low-speed centrifugation for
10 min at 41C. A preservative solution (0.13% e-aminocaproic acid
and 0.1% thiomerosal) was added (10ml/ml) to all plasma samples,
which were shipped in the fresh state by air express mail to the Lipid
and Lipoprotein Laboratory, Oklahoma Medical Research Founda-
tion, for measurements of lipids, apo’s, and lipoprotein particles.
TC, TGs, and HDL-cholesterol (HDL-C) were determined
by standardized enzymic procedures as described previously.12
VLDL-cholesterol (VLDL-C) was assumed to equal one-fifth of the
plasma TG concentration, and LDL-cholesterol (LDL-C) levels
were calculated by the procedure of Friedewald et al.48 TC, TG, and
HDL-C were standardized through the lipid standardization
program of the Centers of Disease Control and Prevention, Atlanta,
GA, USA.
Measurements of apo’s A-I, B, C-III, and E and the quantification
of apoC-III bound to apoA- (HDL) and apoB- (VLDLþ LDL)
containing lipoproteins, performed on heparin-Mnþ þ supernates
(apoC-III-heparin-manganese supernate) and heparin-Mnþ þ pre-
cipitates (apoC-III-heparin-manganese precipitate), were carried
out as described previously.12,49
ApoA- and ApoB-containing lipoprotein subclasses
Plasma concentrations of LpA-I and LpA-I:A-II subclasses of high-
density properties were determined by a differential electroimmu-
noassay on plates containing antisera to apo’s A-I and A-II.50
Determination of plasma levels of five individual apoB-containing
lipoprotein subclasses, LpB, LpB:E, LpB:C, LpB:C:E, and LpA-
II:B:C:D:E, was performed by a modification of the originally
described sequential immunoaffinity chromatography of apoB-
containing lipoproteins.11 Instead of a sequential separation, this
modified procedure is based on a stepwise immunoaffinity chro-
matography using three immunosorbers with affinity-purified
antibodies to apo’s A-II, C-III, and E, respectively. The preparation
of affinity-purified antibodies and the preparation and operation
of immunosorbers have been described previously.11,51,52 In the first
step, aliquots of fresh plasma (0.15–0.3 ml) were applied to
anti-apoA-II, anti-apoC-III, and anti-apoE immunosorbers and
incubated overnight at room temperature (Figure 1). The elution
of unretained (U) and retained (R) fractions and their concentra-
tion to a volume of 1.070.5 ml was carried out as described
previously.11,51–53 After recording the final volumes, the apoB
contents of unretained and retained fractions were quantified by
electroimmunoassay.49
As shown in Figure 1, the retained fraction (R) from immuno-
affinity chromatography of whole plasma on anti-apoA-II immuno-
sorber contained LpA-II:B:C:D:E and the unretained fraction (U)
contained the other four apoB-containing lipoproteins, including
LpB, LpB:C, LpB:E, and LpB:C:E.
The retained fraction (R) from the anti-apoC-III immunosorber
contained apoB-containing lipoprotein families characterized by the
presence of apoC-III (LpB:C, LpB:C:E, and LpA-II:B:C:D:E) and the
unretained fraction (U) contained LpB and LpB:E (Figure 1). Both
the unretained and retained fractions were analyzed for their apoB
contents. The unretained fraction was used for the separation of LpB
and LpB:E.
The retained fraction (R) from the anti-apoE immunosorber
included all apoB-containing lipoproteins in association with apoE
(LpB:E, LpB:C:E, and LpA-II:B:C:D:E), whereas the unretained
fraction (U) contained LpB and LpB:C (Figure 1). ApoB was
determined in both fractions, and the unretained fraction was used
for the separation of LpB and LpB:C.
The purpose of the second step in the separation procedure was
to fractionate unretained fractions from anti-apoC-III and anti-
apoE immunosorbers. The former unretained fraction (apoC-III-U)
was applied to the anti-apoE immunosorber (Figure 1); the retained
fraction contained LpB:E and the unretained fraction contained
LpB. Both fractions were characterized by quantitative determina-
tion of apoB. Similarly, LpB and LpB:C were separated by affinity
chromatography of the unretained fraction from anti-apoE
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immunosorber (apoE-U) (Figure 1). The retained fraction con-
tained LpB:C and the unretained fraction contained LpB.
The concentrations of LpB, LpB:E, and LpB:C and LpA-II:B:C:D:E
were determined and expressed on the basis of apoB concentration
applied to appropriate immunosorbers and apoB recovered in the
corresponding retained and unretained fractions using isolation
schemes depicted in Figure 1. For example, the concentration of LpA-
II:B:C:D:E particles was determined from the known content of
plasma apoB applied to anti-apoA-II immunosorber and apoB
contents recovered in retained and unretained fractions. If the
recovery of apoB in retained and unretained fractions was lower than
100%, the recovered quantities of apoB were corrected to plasma
apoB values; the acceptable recoveries of apoB ranged between 75 and
95%. Although LpB, LpB:E, LpB:C, and LpA-II:B:C:D:E families
were determined directly in their isolated fractions (Figure 1), the
levels of apoB in LpB:C:E particles were calculated as follows:
LpB:C:E¼ apoER(LpB:Eþ LpA-II:B:C:D:E).
The between-assay coefficient variation for LpA-II:B:C:D:E
subclass was 9–10% (retained fraction from anti-apoA-II column).
The between-assay coefficient of variation for LpB:C, LpB:C:E, and
LpA-II:B:C:D:E (retained fraction from anti-apoC-III column) was
8–9% and that for LpB and LpB:E (unretained fraction from anti-
apoC-III column) was 6–7%. The coefficient of variation for LpB:E,
LpB:C:E, and LpA-II:B:C:D:E (retained fraction from anti-apoE
column) was 6–7%, and that for LpB and LpB:C (unretained
fraction from anti-apoE column) was 1–2%.
Other clinical variables
The glomerular filtration rate was determined as the plasma or renal
clearance of 51Cr-ethylenediamine tetraacetate.54 A physical exam-
ination was performed and glomerular filtration rate was deter-
mined at randomization and at the end of the second treatment
period. For safety reasons, blood pressure was measured and a
routine clinical laboratory evaluation was performed at the start and
end of each treatment period. Blood pressure was recorded after
5 min of supine rest.
Statistical methods
Standard statistics were used to illustrate the salient features of data.
Outcome variables were measured before and after each treatment
period. The percentage of change from baseline was calculated for all
efficacy variables. These data were analyzed using a mixed-model
analysis of variance with fixed effects for sequence, period, and
treatment and a random effect for patient within sequence. Analyses
were performed using Statistical Analyzing System version 6.12 (SAS
Institute Inc., Cary, NC, USA). The study was approved by the
Ethical Committee of the University of Go¨teborg (Sweden) under
Study No. 223-96. All patients gave their written informed consent.
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